dcsimg Aranesp® (darbepoetin alfa) – Risk for Transfusion
› Email› Print

Annual transfusion rate is 4 times higher
in patients with Hb < 10 g/dL vs ≥ 10 g/dL1

Annual transfusion rate

Risk for transfusion increased when Hb was < 10 g/dL and remained even after adjusting for clinical factors such as age, race, and comorbidities.1

Monitor Hb frequently and intervene with Aranesp® QW and Q2W dosing to reduce the need for RBC transfusions.2

Dosing Information

  • Physicians and patients should weigh the possible benefits of decreasing transfusions against the increased risks of death and other serious cardiovascular adverse events.
  • Initiate Aranesp® treatment when the Hb level < 10 g/dL.
  • Individualize dosing and use the lowest dose of Aranesp® sufficient to reduce the need for RBC transfusions.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
ESA = erythropoiesis-stimulating agent; Hb = hemoglobin; QW = once weekly; Q2W = once every two weeks.
References: 1. Gilbertson DT, Monda KL, Bradbury BD, Collins AJ. RBC transfusions among hemodialysis patients (1999-2010): influence of hemoglobin concentrations below 10 g/dL. Am J Kidney Dis. 2013;62:919-928. 2. Aranesp® (darbepoetin alfa) prescribing information, Amgen.

Biotechnology by Amgen®